Premium
Biodistribution of 131 I‐labelled monoclonal antibodies in human colon tumours by an ex vivo perfusion model
Author(s) -
Kraas E.,
Löhde E.,
Abri O.,
Schlicker H.,
Matzku S.,
Kalthoff H.,
Schmiegel W.,
Arndt R.
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910410816
Subject(s) - biodistribution , monoclonal antibody , perfusion , antibody , pathology , in vivo , ex vivo , scintigraphy , medicine , biology , nuclear medicine , immunology , microbiology and biotechnology
We describe a model for the evaluation of anti‐tumour antibody specificity, using a human carcinoma‐bearing colon segment. After resection of the human colon tumour, the supplying artery was cannulated and perfused with fresh frozen plasma and heparin. Continuous control of pressure, flow, temperature, pH and various metabolic parameters were performed after administration of 131 I‐labelled anti‐CEA antibody. Highly differentiated adenocarcinomas of the colon showed a much higher antibody uptake than undifferentiated tumours. Between 3 and 7% of the injected antibody was found in the tumour tissue. Autoradiography showed non‐homogeneous binding in the tumour tissue. The non‐specific antibody perfusion showed no tumour binding. We conclude that the ex vivo perfusion of resected colon carcinomas can be used to measure the kinetics of binding and clearance of MAbs in tumour tissue by direct scintigraphy. The cellular biodistribution of the antibody can be documented by means of autoradiography.